Myeloma: Discovery to Therapy April 26-27, 2021 DISCLOSURE of FINANCIAL RELATIONSHIPS

AACR Virtual Special Meeting Myeloma: Discovery to Therapy April 26-27, 2021 DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has pro- vided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

Relationships are abbreviated as follows: E, Employee of listed company, G, Grant/research support recipient, A, Advisor or review panel member, C, Consultant, S, Stock Share- holder, SB, Speakers’ Bureau, H, Honoraria, O, Other.

Last Name First Name Company Relationships Type Role Pfizer, AstraZeneca, Janssen, Precision Program Committee, Anderson Kenneth Dana-Farber Cancer Institute Biosciences, Windmill, C4 Therapeutics, A,C Speaker Oncopep, Starton, Raqia, Mana Arthur Ronald American Association for Cancer Research No Relationships Staff Auclair Daniel Multiple Myeloma Research Foundation No Relationships Speaker Baran Amy American Association for Cancer Research No Relationships Staff Boise Lawrence Emory University AbbVie, AstraZeneca, Genentech A,G Speaker Bristol Myers Squibb, Celgene, Janssen, Takeda, Davies Faith NYU Langone Health A,H Speaker Sanofi, Oncopeptides Dhodapkur Madhav Emory University No Relationships Speaker Amgen, Celgene, Janssen, Takeda, Bristol Gay Francesca University of Torino Myers Squibb, AbbVie, GlaxoSmithKline, Roche, A,H Speaker Adaptive Biotechnologies, Oncopeptides IBM; Pharmacyclics; Scorpion Therapeutics; Getz Gad Broad Institute of MIT and Harvard MuTect, ABSOLUTE, MutSig, MSMuTect, C,G,H,S,O Speaker MSMutSig, POLYSOLVER; TensorQTL.

1 AACR Virtual Special Meeting Myeloma: Discovery to Therapy April 26-27, 2021 DISCLOSURE OF FINANCIAL RELATIONSHIPS Last Name First Name Company Relationships Type Role GlaxoSmithKline, Sanofi, Janssen, Takeda, Celgene, Karyopharm, AbbVie, GNS, Cellectar, Program Committee, Ghobrial Irene Dana-Farber Cancer Institute A,C Medscape, Genetech, Adaptive, Bristol Myers Speaker Squibb, Aptitude Gormley Nicole FDA Center for Drug Evaluation & Research No Relationships Speaker Rapid Payer Response, BMA Foundation, Hillengass Jens Roswell Park Comprehensive Cancer Center A,H Speaker Skyline Diagnostics, Sanofi, Oncopeptides University of Miami Sylvester Comprehensive Amgen, Janssen, IDMC, Adaptive Biotech, Landgren Ola A,C,SB Speaker Cancer Center Bristol Myers Squibb Bristol Myers Squibb, Celgene, GlaxoSmithKline, Madduri Deepu Icahn School of Medicine at Mount Sinai Sanofi, Janssen, Kinevant, Foundation Medicine, C,E Speaker Amgen, Regeneron, Allogene, Mount Sinai Manier Salomon University of Lille No Relationships Speaker Janssen, Celgene, Amgen, Takeda, Mateos María-Victoria University of Salamanca GlaxoSmithKline, Oncopeptides, Sanofi, Pfizer, H Speaker Regeneron, Sea-Gen, Roche University of Miami Sylvester Comprehensive Maura Francesco No Relationships Speaker Cancer Center McDonald Richard Richard McDonald Household No Relationships Speaker Sanofi, Arch Oncology, Merck KGaA/EMD Serono, Abbvie, Karyopharm, Janssen/ Mitsiades Constantine Dana-Farber Cancer Institute Johnson & Johnson, TEVA, Nurix, C,G,H Speaker H3 Biosciences, Fate Therapeutics, Ionis Pharmaceuticals, FIMECS Abbvie, Adapative, Amgen, Celgene, Janssen, Munshi Nikhil Dana-Farber Cancer Institute C,S Speaker Karyopharm, Takeda, Oncopep, Inc.

2 AACR Virtual Special Meeting Myeloma: Discovery to Therapy April 26-27, 2021 DISCLOSURE OF FINANCIAL RELATIONSHIPS Last Name First Name Company Relationships Type Role Neri Paola University of Calgary Janssen, Bristol Myers Squibb A,H Speaker Bristol Myers Squibb, Celgene, AbbVie, Amgen, Raab Marc Heidelberg University Hospital (UKHD) Janssen, Novartis, Takeda, Heidelberg Pharma, A,C,H Speaker GlaxoSmithKline, Regeneron, Sanofi, Pfizer Celgene-Bristol Myers Squibb, Janssen, Amgen, Rodríguez-Otero Paula University of Navarra GlaxoSmithKline, Kite Pharma, Sanofi, AbbVie, A,H Speaker Oncopeptides Bristol Myers Squibb, Fate Therapeutics, Smith Eric Dana-Farber Cancer Institute C,G,O Speaker Chimeric Therapeutics Tendler Craig Johnson & Johnson Pharmaceutical R&D Johnson and Johnson E Speaker Walker Brian University of Arkansas for Medical Sciences No Relationships Speaker